Latest News

Axsome’s stock falls after disclosing Teva’s plans to market generic Auvelity


Shares of Axsome Therapeutics Inc.

tumbled about 10.0% in premarket trading on Monday after the company said in a securities filing that Teva Pharmaceutical Industries Ltd.

is seeking approval from the Food and Drug Administration to market a generic version of Auvelity, Axsome’s depression treatment. Axsome’s stock has gained 95.8% over the past year, while the S&P 500

declined 7.6%.

Item 8.01 Other Events.

Warren Buffett says he doesn’t own bitcoin because ‘it isn’t going to do anything’ — he’d rather own these 2 highly coveted and productive assets instead

Previous article

The Motley Fool Scam: Separating Fact from Fiction

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News